Abstract:The increasing prevalence of neurodegenerative diseases constitutes a significant challenge to public health systems globally. Consequently, the quest for efficacious preventive and therapeutic strategies has assumed center stage in public health discourse. Animal models serve as indispensable instruments in neurodegenerative disease research, offering foundational data that inform our understanding of the pathological mechanisms and contribute to the development of novel therapeutic paradigms. This manuscript delineates the methodologies for constructing animal models germane to prevalent neurodegenerative conditions such as Alzheimer’s Disease, Parkinson’s Disease, and Amyotrophic Lateral Sclerosis. The establishment of these models incorporates factors like genetic etiology, pathological signatures, and the temporal course of disease progression. Traditional techniques in model development frequently exhibit shortcomings in disease specificity, phenotypic stability, and alignment with the pathological evolution of human ailments. However, advancements in gene-editing technologies, notably CRISPR/Cas9, facilitate the emulation of human neurodegenerative disease pathologies with increased precision. This augments the relevance of animal models as instrumental tools in pharmaceutical development and the formulation of disease prevention strategies. In addition to conventional neurodegenerative animal models, the manuscript explores advancements in innovative models including chemical induction models, human brain tissue transplantation models, spontaneous models, and accelerated aging models. A focal point of the discourse is the transformative impact of gene-editing technologies on animal model development, with emphasis on the theoretical foundations and methodologies for creating polygenic breeding models and genetically diverse, gene-edited models. 1. Key gene-editing technologies applied in the domain of animal model creation encompass gene knock-in/knock-out, RNA interference (RNAi), and CRISPR/Cas9. Gene knock-in entails the integration of a target gene into a predetermined genomic location, while gene knock-out involves the excision of a specific gene, either entirely or partially. Both processes are predicated on homologous recombination, leveraging the innate capability of DNA molecules for homologous pairing and exchange to insert the target gene at precise chromosomal loci. 2. Complex human diseases frequently involve an array of genes or quantitative trait loci (QTL), each exerting a modest impact on the disease phenotype. When multiple QTLs are inherited, disease manifestation or predisposition may ensue. The advancement of mouse models for Alzheimer’s Disease epitomizes this intricate multi-gene or multi-locus modification process. As stronger genetic drivers and their combinations are identified, the selection and arrangement of divergent mouse strains can refine these models further. 3. The utility of genetically diverse gene-edited animal models lies in their ability to replicate human genetic variability by exploiting the phenotypic differences inherent in mice with assorted genetic backgrounds. The integration of gene-edited animal models into neurodegenerative disease research enhances our mechanistic understanding of these conditions. The manuscript elucidates emergent research avenues in gene-edited animal models, including the capabilities of polygenic models to emulate intricate disease states and the evolving role of comorbidity models. These tools are pivotal for a comprehensive understanding of disease pathogenesis, the elucidation of environmental and genetic interactions, the screening of pharmaceutical candidates, and the conception of innovative therapeutic interventions. Although existing models fail to capture the full complexity of human diseases, there is a rational expectation that ongoing technological innovations will ameliorate these limitations, thereby influencing the future trajectory of neurodegenerative disease research.

CRISPR-engineered genome editing for the next generation neurological disease modeling

Genome Editing in iPSC-Based Neural Systems: From Disease Models to Future Therapeutic Strategies

[Applications of ZFN, TALEN and CRISPR/Cas9 Techniques in Disease Modeling and Gene Therapy].

Use of CRISPR/Cas9 to Model Brain Diseases

CRISPR/Cas9: Implications for Modeling and Therapy of Neurodegenerative Diseases

CRISPR/Cas9: Implications for Modeling and Therapy of Neurodegenerative Diseases.

Next Generation Precision Medicine: CRISPR-mediated Genome Editing for the Treatment of Neurodegenerative Disorders

CRISPR/Cas9: a powerful genetic engineering tool for establishing large animal models of neurodegenerative diseases

Application and perspective of CRISPR/Cas9 genome editing technology in human diseases modeling and gene therapy

Strategy for Applying CRISPR/Cas9 Gene Editing Technology in Neuroscience

The Application of CRISPR/Cas9 Technology in Neurological Diseases

Development and application of CRISPR/Cas9 technologies in genomic editing.

CRISPR/Cas9-Based Genome Editing for Disease Modeling and Therapy: Challenges and Opportunities for Nonviral Delivery.

CRISPR-Based Gene Editing Techniques in Pediatric Neurological Disorders

Vector enabled CRISPR gene editing – A revolutionary strategy for targeting the diversity of brain pathologies

The Establishment and Application of Animal Models for Neurodegenerative Diseases

A Rapid Pipeline to Model Rare Neurodevelopmental Disorders with Simultaneous CRISPR/Cas9 Gene Editing

CRISPR and iPSCs: Recent Developments and Future Perspectives in Neurodegenerative Disease Modelling, Research, and Therapeutics

CRISPR/Cas9: implication for modeling and therapy of amyotrophic lateral sclerosis

Applications of CRISPR-Cas9 in Alzheimer’s Disease and Related Disorders

Efficient in vivo neuronal genome editing in the mouse brain using nanocapsules containing CRISPR-Cas9 ribonucleoproteins